Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 2 of the 16 sources its claims cite were checked for support.

Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial

Open access
· 2015 · The Lancet

Abstract

BACKGROUND: Early mobilisation after stroke is thought to contribute to the effects of stroke-unit care; however, the intervention is poorly defined and not underpinned by strong evidence. We aimed to compare the effectiveness of frequent, higher dose, very early mobilisation with usual care after stroke. METHODS: We did this parallel-group, single-blind, randomised controlled trial at 56 acute stroke units in five countries. Patients (aged ≥18 years) with ischaemic or haemorrhagic stroke, first or recurrent, who met physiological criteria were randomly assigned (1:1), via a web-based computer generated block randomisation procedure (block size of six), to receive usual stroke-unit care alone or very early mobilisation in addition to usual care. Treatment with recombinant tissue plasminogen activator was allowed. Randomisation was stratified by study site and stroke severity. Patients, outcome assessors, and investigators involved in trial and data management were masked to treatment allocation. The primary outcome was a favourable outcome 3 months after stroke, defined as a modified Rankin Scale score of 0-2. We did analysis on an intention-to-treat basis. The trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12606000185561. FINDINGS: Between July 18, 2006, and Oct 16, 2014, we randomly assigned 2104 patients to receive either very early mobilisation (n=1054) or usual care (n=1050); 2083 (99%) patients were included in the 3 month follow-up assessment. 965 (92%) patients were mobilised within 24 h in the very early mobilisation group compared with 623 (59%) patients in the usual care group. Fewer patients in the very early mobilisation group had a favourable outcome than those in the usual care group (n=480 [46%] vs n=525 [50%]; adjusted odds ratio [OR] 0·73, 95% CI 0·59-0·90; p=0·004). 88 (8%) patients died in the very early mobilisation group compared with 72 (7%) patients in the usual care group (OR 1·34, 95% CI 0·93-1·93, p=0·113). 201 (19%) patients in the very early mobilisation group and 208 (20%) of those in the usual care group had a non-fatal serious adverse event, with no reduction in immobility-related complications with very early mobilisation. INTERPRETATION: First mobilisation took place within 24 h for most patients in this trial. The higher dose, very early mobilisation protocol was associated with a reduction in the odds of a favourable outcome at 3 months. Early mobilisation after stroke is recommended in many clinical practice guidelines worldwide, and our findings should affect clinical practice by refining present guidelines; however, clinical recommendations should be informed by future analyses of dose-response associations. FUNDING: National Health and Medical Research Council, Singapore Health, Chest Heart and Stroke Scotland, Northern Ireland Chest Heart and Stroke, UK Stroke Association, National Institute of Health Research.

Overview

CoChat Summary

TL;DR

In AVERT, very early mobilisation (frequent, higher-dose out-of-bed activity within 24 h) reduced the odds of a favourable outcome at 3 months compared with usual care, with no significant difference in death or serious adverse events. The trial suggests an early, lower-dose usual-care activity regimen may be preferable to very early, frequent, higher-dose intervention.

Key findings

  • 2104 patients were randomly assigned to very early mobilisation (n=1054) or usual care (n=1050); 2083 (99%) were included in the 3-month follow-up. 965 (92%) very early mobilisation patients were mobilised within 24 h versus 623 (59%) usual care patients; median time to first mobilisation was 18·5 h versus 22·4 h (median shift 4·8 h).
  • The primary outcome, favourable modified Rankin Scale score 0–2 at 3 months, occurred in 480 (46%) very early mobilisation patients versus 525 (50%) usual care patients (adjusted OR 0·73, 95% CI 0·59–0·90; p=0·004). The ordinal modified Rankin Scale analysis was not significant (generalised OR 0·94, 95% CI 0·85–1·03; p=0·193).
  • Death occurred in 88 (8%) very early mobilisation patients versus 72 (7%) usual care patients (OR 1·34, 95% CI 0·93–1·93; p=0·113). Non-fatal serious adverse events occurred in 201 (19%) versus 208 (20%) patients (IRR 0·88, 95% CI 0·72–1·07; p=0·194), with no reduction in immobility-related complications.
  • There was no evidence of accelerated walking recovery: walking 50 m unassisted adjusted OR 0·83 (95% CI 0·64–1·07; p=0·143); time to walking unassisted HR 1·04 (95% CI 0·94–1·15; p=0·459). Prespecified subgroup analyses showed no significant interactions, though point estimates suggested reduced odds of favourable outcome in severe stroke and intracerebral haemorrhage subgroups with wide confidence intervals.

Methods

  • Pragmatic, parallel-group, single-blind, multicentre, international randomised controlled trial at 56 acute stroke units in Australia, New Zealand, Malaysia, Singapore, and the UK. Eligible patients were aged ≥18 years with confirmed first or recurrent ischaemic or haemorrhagic stroke admitted to a stroke unit within 24 h of onset and meeting physiological criteria; exclusions included premorbid modified Rankin Scale score >2, early deterioration, and other serious medical instability.
  • Patients were randomly assigned 1:1 via a secure, remote, web-based computer-generated block randomisation procedure (block size six), stratified by study site and baseline NIHSS stroke severity (mild 1–7, moderate 8–16, severe >16). The very early mobilisation intervention began within 24 h, focused on sitting, standing, and walking out-of-bed activity, and resulted in at least three additional out-of-bed sessions to usual care, with titrated dose for 14 days or until discharge.
  • The primary outcome was favourable outcome at 3 months, defined as modified Rankin Scale score 0–2. Analysis was intention-to-treat; primary efficacy used binary logistic regression adjusted for baseline age and NIHSS. The trial was powered to detect an absolute risk reduction of poor outcome of 7·1% or greater, with a target sample of 2104 patients.

Limitations

  • The paper states that large trials yield limited information about potential confounders such as physiological variables and about each staff–patient interaction, restricting but not preventing further detailed analyses.
  • The pragmatic design did not prescribe usual care mobilisation practices, which changed significantly during the trial; usual care clinicians started mobilisation earlier each year, with roughly 60% of usual care patients starting out-of-bed therapy within 24 h. Whether this reflected contamination from the trial protocol, changing attitudes/guidelines, or both is uncertain.
  • The study was not powered to detect subgroup differences; subgroup signals for severe stroke and intracerebral haemorrhage had wide confidence intervals and no significant interactions, so the paper advises caution. The text also notes the proportional hazards assumption was violated for the time-to-walking analysis, and missing data were handled under a missing-at-random assumption with sensitivity analyses.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)60690-0

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 1 Not valid · 12 Not checked · 60 Own results and interpretations

30 more claims

Create a free account to see all 75 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 22

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 26 references

Cited by

See all 789

Metadata

Venue
The Lancet
Publisher
Elsevier BV
Published
2015-07
Volume
386
Issue
9988
Pages
46-55
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2096535216
Cited by
789
References
26
Citations by year
2026: 55 · 2025: 58 · 2024: 44 · 2023: 57 · 2022: 79 · 2021: 93 · 2020: 87 · 2019: 77 · 2018: 72 · 2017: 75 · 2016: 67 · 2015: 24
FWCI
79.96
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, cc-by-nc-nd)
  • Figshare (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
Funders
National Health and Medical Research Council (NHMRC) of Australia (grant numbers 386201 and 1041401)
Topics
  • Health Sciences › Medicine › Rehabilitation › Stroke Rehabilitation and Recovery
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Health Professions › Speech and Hearing › Dysphagia Assessment and Management
Keywords
stroke, acute stroke, ischemic stroke, hemorrhagic stroke, stroke unit care, functional outcome, modified Rankin Scale, mortality, stroke rehabilitation, thrombolysis, tissue plasminogen activator, stroke severity
MeSH terms
Stroke Rehabilitation, Aged, Aged, 80 and over, Early Ambulation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Severity of Illness Index, Time Factors, Single-Blind Method, Walking, Treatment Outcome, Recovery of Function, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)60690-0
The paper
Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. (2015). The Lancet. https://doi.org/10.1016/s0140-6736(15)60690-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.